GlassScriptPhysician profile
Roger W Thompson
NPI 1841721776
$3,952.97
in general payments reported to CMS, 2019-2025
29 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $479 · 2021: $603 · 2022: $952 · 2023: $749 · 2024: $669 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $495.00 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $462.94 | 2020-2024 | Xarelto |
| Abiomed | $401.18 | 2021-2023 | Impella |
| Pfizer INC. | $368.70 | 2021-2025 | |
| Atricure, INC. | $261.96 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Boston Scientific Corporation | $230.41 | 2021-2024 | Watchman Flx, Watchman Access System |
| Lantheus Medical Imaging, INC. | $200.50 | 2021-2023 | Definity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.52 | 2021-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.57 | 2022 | |
| Shockwave Medical, INC | $129.54 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cvrx, INC. | $118.54 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $103.74 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $93.73 | 2020-2025 | Wainua, Farxiga |
| Amgen INC. | $88.32 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $79.30 | 2024-2025 | Opsumit, Uptravi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $75.55 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $68.42 | 2023-2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $62.90 | 2023 | Arcalyst |
| Novo Nordisk INC | $48.18 | 2021-2025 | Ozempic |
| Inspire Medical Systems, INC. | $47.91 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $41.15 | 2022-2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $40.77 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $39.21 | 2020-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $24.18 | 2025 | |
| Heartflow, INC. | $22.75 | 2024 | |
| Vital Connect, INC | $20.00 | 2024 | Vitalpatch Rtm |
| Irhythm Technologies, INC. | $17.72 | 2023 | Zio Xt Patch |
| United Therapeutics Corporation | $16.73 | 2023 | Tyvaso |
| Edwards Lifesciences Corporation | $16.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.